While a direct inhibitor specifically designed to target C14orf105 is not identified in the class of C14orf105 inhibitors, the indirect inhibitors that can affect this protein would typically act on the cellular pathways to which C14orf105 is integral. Inhibitors within this class would the capacity to bind to and modulate the activity of upstream regulators or downstream effectors of C14orf105, thereby altering its function. These compounds achieve their inhibitory action through well-established molecular interactions, such as competitive inhibition, allosteric modulation, or interference with substrate processing, ultimately leading to a decrease in the activity or stability of C14orf105.
The diversity of the C14orf105 inhibitors class reflects the broad spectrum of possible interactions within cellular signaling pathways. For example, assuming C14orf105 is a component of a kinase-dependent signaling pathway, kinase inhibitors would be pertinent members of this class. These inhibitors work by preventing phosphorylation events that are necessary for the propagation of a signal to C14orf105, thus reducing its activity. Similarly, in terms of proteasomal degradation, proteasome inhibitors could lead to an accumulation of proteins that may include C14orf105, affecting its turnover and function. The specificity of these inhibitors would stem from their ability to selectively interact with their targets, influencing the biochemical pathways that govern the function of C14orf105 without the necessity to bind directly to the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, which may affect downstream signaling potentially impacting proteins like C14orf105. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, affecting the MAPK/ERK pathway which could have consequences for related proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase potentially altering signaling pathways involving related proteins. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could affect proteins associated with the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Acts as a PI3K inhibitor, potentially influencing downstream proteins in PI3K-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which may indirectly impact proteins involved in the mTOR signaling pathway. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
Inhibits Rac1, potentially affecting proteins linked to the Rac1 signaling pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK, potentially impacting related proteins in the Rho/ROCK signaling pathway. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
Inhibits Aurora kinase, which may affect proteins related to cell cycle regulation and mitosis. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Inhibits Src family kinases, potentially altering signaling pathways involving related proteins. | ||||||